GlaxoSmithKline plc (LON:GSK) had its price objective cut by Kepler Capital Markets from GBX 1,520 ($20.06) to GBX 1,340 ($17.68) in a report published on Wednesday morning. They currently have a reduce rating on the stock.
A number of other equities research analysts also recently commented on the stock. Citigroup Inc. downgraded shares of GlaxoSmithKline plc from a buy rating to a neutral rating and set a GBX 1,700 ($22.43) price objective on the stock. in a research report on Wednesday, July 5th. Jefferies Group LLC reissued a buy rating and issued a GBX 1,900 ($25.07) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. J P Morgan Chase & Co reissued a neutral rating and issued a GBX 1,750 ($23.09) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. Shore Capital reissued a hold rating on shares of GlaxoSmithKline plc in a research report on Friday, July 14th. Finally, Morgan Stanley reissued an equal weight rating and issued a GBX 1,700 ($22.43) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, July 18th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of GBX 1,619.75 ($21.37).
Shares of GlaxoSmithKline plc (LON:GSK) opened at GBX 1,361 ($17.96) on Wednesday.
GlaxoSmithKline plc (LON:GSK) last announced its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share for the quarter, topping the consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a negative net margin of 1.17% and a negative return on equity of 57.19%. The firm had revenue of GBX 784.30 billion for the quarter.
The company also recently declared a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, November 9th. This represents a dividend yield of 1.41%.
In related news, insider Urs Rohner bought 473 shares of the firm’s stock in a transaction that occurred on Wednesday, October 25th. The shares were acquired at an average cost of GBX 1,518 ($20.03) per share, with a total value of £7,180.14 ($9,474.98). Also, insider Simon Dingemans bought 1,076 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The stock was bought at an average cost of GBX 1,527 ($20.15) per share, for a total transaction of £16,430.52 ($21,681.87). Insiders purchased 1,574 shares of company stock worth $2,398,888 over the last three months.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with our FREE daily email newsletter.